CareDx, Inc. is a medical diagnostics company focused on the discovery, development, and commercialization of testing solutions for the organ transplant sector. The company's business model centers on providing proprietary molecular tests and digital solutions that assist clinicians in matching donors and monitoring patients before and after transplant surgery. CareDx generates the majority of its revenue (approximately 73%) from its testing services, which are performed at its CLIA-certified laboratory. Key products in this segment include AlloSure, a donor-derived cell-free DNA (dd-cfDNA) test used to detect organ rejection in kidney, heart, and lung transplant recipients, and AlloMap, a gene expression profiling test for heart transplant patients. In addition to testing services, CareDx derives about 14% of its revenue from patient and digital solutions, offering software like Ottr to help transplant centers manage patient data and clinical workflows. The remaining 12% of revenue comes from laboratory products, including Olerup SSP and QTYPE, which are human leukocyte antigen (HLA) typing technologies used for pre-transplant donor matching. Headquartered in South San Francisco, California, with additional operations in Nebraska and Sweden, CareDx serves a specialized market of transplant centers, hospitals, and reference laboratories globally. The company's competitive position is supported by its comprehensive suite of transplant-focused diagnostics and its integration into the clinical workflows of major transplant programs.
